Investing.com -- Shares of Guardant Health (NASDAQ:GH) have increased by 5.0% in premarket trading Tuesday following the ...
Tissue-free Guardant Reveal test identifies disease progression up to 18 months earlier than standard clinical measures in patients with advanced cancer Longitudinal circulating tumor DNA (ctDNA) ...
New Guardant Reveal offering provides oncologists with tissue-free solution to monitor treatment response and detect early disease progression with unprecedented speed and sensitivity Reveal is ...
Medicare now covers Guardant Reveal for monitoring colorectal cancer recurrence after curative therapy. Analyst sees expanded coverage boosting revenue and improving gross margins by year-end. Ready ...
The first readout from Guardant’s research collaboration with the Parker Institute for Cancer Immunotherapy (PICI) shows Guardant Reveal detected responses to immunotherapy across multiple tumor types ...
Guardant Health is touting the results of a new study showing its Reveal blood test can detect whether chemotherapy is failing months before evidence shows up on regular scans, allowing oncologists to ...
Spotlight presentation using Guardant Reveal™ test suggests ctDNA has potential to predict sensitivity to endocrine therapy and long-term outcomes in HR+ breast cancer Guardant and its research ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating that its Guardant Reveal® blood test helps clinicians to assess the effectiveness of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results